IL-2 treatment after autologous bone marrow transplantation in poor prognosis Hodgkin's disease: defective IL-2-induced LAK activity?
Tiberghien
P
P
Bone Marrow Transplantation Unit, C.H.U.J. Minjoz, Besancon, France.
Racadot
E
E
Fest
T
T
Lioure
B
B
Pariset
J
J
Delain
M
M
Voillat
L
L
Flesch
M
M
Amsallem
D
D
Plouvier
E
E
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D006689:Hodgkin Disease / Q000276:immunology / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000494:pharmacology / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D014182:Transplantation, Autologous
D007155:Immunologic Factors; D007376:Interleukin-2